Class action alleges “no-generics” collusion by Gilead
Several activists and two employee benefit funds have sued Gilead and three other drugmakers for allegedly colluding to limit generic competition for treatment of human immunodeficiency virus.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10